{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Duraj T"],"pubmed_abstract":["Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a universally lethal prognosis despite maximal standard therapies. Here, we present a consensus treatment protocol based on the metabolic requirements of GBM cells for the two major fermentable fuels: glucose and glutamine. Glucose is a source of carbon and ATP synthesis for tumor growth through glycolysis, while glutamine provides nitrogen, carbon, and ATP synthesis through glutaminolysis. As no tumor can grow without anabolic substrates or energy, the simultaneous targeting of glycolysis and glutaminolysis is expected to reduce the proliferation of most if not all GBM cells. Ketogenic metabolic therapy (KMT) leverages diet-drug combinations that inhibit glycolysis, glutaminolysis, and growth signaling while shi"],"journal":["BMC medicine"],"pagination":["578"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11622503"],"repository":["biostudies-literature"],"pubmed_title":["Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma."],"pmcid":["PMC11622503"],"pubmed_authors":["Cooper I","Kiebish M","Chaffee A","Phillips MCL","Omene E","Arismendi-Morillo G","Dietrich J","Kofler B","Worden D","Schwartz KA","Elsamman AK","Abdel-Hadi W","Pflueger A","Winter SF","Hagihara K","Champ CE","Hu J","Cincione RI","Mukherjee P","Duraj T","Kalamian M","Tan-Shalaby J","Seyfried TN","D'Agostino DP","Scheck AC","Hickson A","Evangeliou AE","Poff A","Yanagisawa A","Yu GW","Slocum AK","El-Sakka AM","Clemens Z","Serfaty FM","Cheng R","Lee DC","Spinosa JP","Klein P","Pilkington GJ","Klement RJ","Nathan JK","Smith K","Maroon JC","Zupec-Kania B","Fortin D","Zuccoli G","Mathews EH","Iyikesici MS","Shi H"],"additional_accession":[]},"is_claimable":false,"name":"Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.","description":"Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a universally lethal prognosis despite maximal standard therapies. Here, we present a consensus treatment protocol based on the metabolic requirements of GBM cells for the two major fermentable fuels: glucose and glutamine. Glucose is a source of carbon and ATP synthesis for tumor growth through glycolysis, while glutamine provides nitrogen, carbon, and ATP synthesis through glutaminolysis. As no tumor can grow without anabolic substrates or energy, the simultaneous targeting of glycolysis and glutaminolysis is expected to reduce the proliferation of most if not all GBM cells. Ketogenic metabolic therapy (KMT) leverages diet-drug combinations that inhibit glycolysis, glutaminolysis, and growth signaling while shi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-21T21:50:22.766Z","creation":"2025-04-21T21:50:22.766Z"},"accession":"S-EPMC11622503","cross_references":{"pubmed":["39639257"],"doi":["10.1186/s12916-024-03775-4"]}}